



### **Factors Influencing the Delivery of Cancer Pathways: A Summary of the Literature**

Journal:	<i>Journal of Health Organization and Management</i>
Manuscript ID	JHOM-05-2020-0192.R3
Manuscript Type:	Original Article
Keywords:	Qualitative mapping, cancer care pathways, treatment, access barriers, literature review, diagnostics

## Abstract

**Purpose:** Issues on timely access to diagnosis and treatment for cancer patients are still common. Many countries developed cancer care pathways to standardise and improve the outcomes of the services. Despite the existence of the cancer pathways, health services are still struggling to deliver timely cancer care. The study aims to summarise the literature on cancer care pathways at the diagnostic and treatment phases. The objectives are to find factors influencing the delivery of cancer care pathways; to highlight any interrelating factors; to find gaps in the literature concerning areas of research; to summarise the strategies and recommendations implemented in the studies.

**Design/methodology/approach:** The study used a qualitative approach and developed a causal loop diagram to summarise the current literature on cancer care pathways, from screening and diagnosis to treatment. A total of 46 papers was finally included in the analysis, which highlights the recurring themes in the literature.

**Findings:** The study highlights the myriad areas of research applied to cancer care pathways. Factors influencing the delivery of cancer pathways were classified into different albeit interrelated themes. These include access barriers to care, hospital emergency admissions, fast track diagnostics, delay in diagnosis, waiting time to treatment, and strategies to increase system efficiency.

**Originality/value:** As far as the authors know, this is the first study to present a visual representation of the complex relationship between factors influencing the delivery of cancer care pathways.

1  
2  
3  
4  
5  
6  
7  
8        *Keywords:* Qualitative mapping, cancer care pathways, diagnostics,  
9 treatment, access barriers, literature review  
10

---

## 11 12 13 14 15        **1. Introduction**

16  
17        A care pathway can be defined as a general clinical plan that maps  
18 the trajectory of the patient through the healthcare system (Altini *et al.*,  
19 2020; Schrijvers *et al.*, 2012). As such, it involves many activities and  
20 can be seen as a complex adaptive system that responds to medical  
21 decisions, patient outcomes and local characteristics, among other  
22 factors. Indeed, care pathways are subjected to a complex interplay of  
23 factors that can be captured, for example using causal loop diagrams  
24 (Littlejohns *et al.*, 2018; Sterman, 2000).  
25  
26  
27  
28  
29  
30

31        The importance of proper management and a clear understanding of  
32 the impact of care pathways in the quality of care is acknowledged in the  
33 literature (Allen *et al.*, 2019). It is often argued that the input of patients,  
34 as well as healthcare specialists, is essential in the design of effective  
35 care pathways (Donetto *et al.*, 2019). Whilst the design of care pathways  
36 to provide better patient experience and improved outcomes is an  
37 important area in the literature (Currie and Harvey, 2000; Lawson *et al.*,  
38 2006), this paper focuses on the analysis of the delivery of cancer care  
39 pathways to understand the complex interaction of factors that ultimately  
40 affect the quality of the service delivered to the patient.  
41  
42  
43  
44  
45  
46  
47  
48

49        Cancer is regarded as the second leading cause of death worldwide  
50 and accounts for approximately one in every six deaths around the globe  
51 (World Health Organization, 2018). It is estimated that half of the UK  
52 population will develop cancer in their lifetime (Queen Mary University  
53 of London, 2017).  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8 Problems related to the availability and delivery of cancer care are  
9 common (Prager *et al.*, 2018). The issues include the accessibility of  
10 cancer care services such as screening, diagnosis, treatment, and the  
11 unpredictability in the delivery of these services (Wang and Onega,  
12 2015). Several countries have developed standardised pathways for  
13 cancer patients to address the latest issue and improve patient outcomes.  
14 Descriptions of standardised lung cancer pathways in Australia, the UK  
15 and Canada can be found in Department of Health and Human Services  
16 (2016); Lung Clinical Expert Group (2017); Cancer Care Ontario  
17 (2019), respectively. Elsewhere, standardised pathways for cancer care  
18 have been found to correlate with improved survival rates for patients  
19 with seven distinct types of cancer in Denmark (Jensen *et al.*, 2017). The  
20 pathways also contributed to the reduction of the diagnostic interval, i.e.  
21 the time elapsed from initial presentation to final diagnosis (Weller *et*  
22 *al.*, 2012). Some studies have associated the implementation of  
23 standardised cancer pathways with increased efficiency, improved  
24 outcomes, and higher patient satisfaction levels (e.g., Delilovic *et al.*,  
25 2019; Gesme and Wiseman, 2011). However, negative effects have also  
26 been identified, such as longer waiting times for patients competing for  
27 the same resources (e.g., Delilovic *et al.*, 2019). This suggests that  
28 research on the implementation of standardised pathways that use shared  
29 resources should also consider the different patient groups sharing the  
30 resources.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 Patient profiles may vary, and even the experiences of similar patients  
50 may be significantly different. Generally, variations may be due to the  
51 underlying heterogeneity of a patient's physical health and behaviours,  
52 professional uncertainty, external constraints, or diffusion of new  
53 knowledge and practices (Alzahouri *et al.*, 2008). For example, similar  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8 patients may undertake distinct diagnostic procedures (Alzahouri *et al.*,  
9 2008); or the indications and the choice of emergency surgery  
10 procedures may vary according to local conditions (Bosscher *et al.*,  
11 2015). These uncertainties may further complicate an already involved  
12 decision making process, but one way to mitigate their influence is by  
13 designing tools and patient pathways that benefit from multidisciplinary  
14 team discussions (Bosscher *et al.*, 2015).  
15  
16  
17  
18  
19

20 A report from the Organisation for European Cancer Institutes  
21 Accreditation and Designation program suggested that different cancer  
22 centres tend to have different numbers of pathologies with dedicated  
23 clinical pathways (Saghatchian *et al.*, 2014). The variation also exists in  
24 the implementation of pathways with waiting time targets. In the UK,  
25 the National Health Service (NHS) guidelines established maximum  
26 waiting times of 2 weeks from referral to outpatient appointment and 62  
27 days from referral to first treatment (Department of Health, 2007).  
28  
29  
30  
31  
32  
33

34 Literature review studies have explored factors relating to cancer care  
35 delivery, albeit with different focuses. The effect of case management in  
36 cancer care could not be ascertained due to the scarcity of literature and  
37 variations in methodology (Wulff *et al.*, 2008). On the other hand, delays  
38 due to both the practitioner and the patient have been correlated with  
39 similar risk factors, such as demographic, socio-economic, education,  
40 and health conditions (Macleod *et al.*, 2009). In addition, the lack of  
41 knowledge about cancer symptoms and the benefits of treatment were  
42 found to influence the delays in accessing the service (Akuoko *et al.*,  
43 2017; Jones *et al.*, 2014; Williams *et al.*, 2019).  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 The aforementioned literature studies have investigated factors  
54 related to either delay in the presentation or diagnosis and treatment. In  
55 contrast, this study aims to summarise the literature on the delivery of  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8 cancer care pathways, covering the studies from presentation to  
9 diagnosis and treatment. The objectives include investigating the factors  
10 associated with the timely and effective delivery of the cancer pathways,  
11 highlighting any interrelating factors, summarising the implemented  
12 strategies for delivering cancer pathways, and reporting gaps in the  
13 literature.  
14  
15  
16  
17

## 18 **2. Methodology**

19  
20  
21 The literature search was conducted in March 2020 and covered  
22 SCOPUS, Science Direct, MEDLINE, PubMed, Web of Science, and  
23 PMC. The search used the following keywords: cancer\* AND  
24 (“diagnostic pathway\*” OR “patient pathway\*” OR “care pathway\*”  
25 OR “critical pathway\*” OR “care map\*” OR “clinical pathway\*”). We  
26 constrained ourselves to studies written in English in the last 20 years.  
27 We excluded studies that covered topics related to testing devices,  
28 development of tools, genetic testing, tumour growth, and surgical  
29 procedures. The quality of the papers was not considered. The selection  
30 process was administered by the lead author. The result was presented,  
31 discussed, and disseminated to the team members who gave suggestions  
32 and contributed to the writing of the paper.  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 Figure 1 summarises the selection process. The first filter identified  
43 1,969 potential studies. This number reduced to 296 following the  
44 removal of duplicates and screening based on titles and abstracts. It was  
45 further trimmed to 151 after excluding content that did not comply with  
46 the inclusion criteria. Finally, 105 studies were excluded due to reasons  
47 such as being related to palliative or supportive care and not concerning  
48 the delivery of cancer pathways. This resulted in the selection of 46  
49 papers for further analysis.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### 2.1. Causal loop diagram for cancer care pathways

Causal loop diagrams (Sterman, 2000) are a system's dynamics tool developed to convey the interplay of factors in complex social systems by promoting a holistic view of the problem at hand. The rationale is to develop a diagram that conveys the existing relationships between pairs of factors to unveil a complete picture of the system to stakeholders and decision-makers.

The present study develops a causal loop diagram to highlight the causal link or relationship between each pair of factors/topics (also dubbed *variables*) investigated in the studies. In order to simplify the analysis whilst also retaining the essence of the articles, we make use of the topics that appear more frequently across all studies. The links between pairs of factors (variables) are represented by arrows in the resulting diagram. The arrows may be non-directional, when the relationship exists but no causality is attributed. Another type of arrow is uni-directional when the direction of causality is established. This type of arrow will have polarity (i.e. an established direction). The diagram does not capture any bi-directional relationship, since such a type of relationship was not found in the studies. It is important to note that the use of the tool is to facilitate the description of relationships between factors. These may not necessarily represent causality.

The factors were selected from the surveyed studies, as well as their pairwise relationships. For the sake of illustration, consider for example a study by Hansen *et al.* (2008) that investigated factors related to delay in cancer diagnosis. The study found that patients' socio-economic situation and age correlated with the delay in cancer diagnosis. Based on these results, the socio-economic and age factors were linked to patient delay in the diagram, see Figure 9.

1  
2  
3  
4  
5  
6  
7  
8 The causal loop diagram was built using the software Vensim PLE,  
9 version 7.3.5 from Ventana Systems Inc (<https://vensim.com>).  
10 Individual analyses of specific themes were also carried out to describe  
11 pertinent variables following the surveyed literature.  
12  
13  
14  
15

### 16 **3. Results**

17  
18 Figure 2 highlights the number of works published yearly from 2008  
19 to 2020. It displays an upward tendency in the number of yearly  
20 publications from 2012 to 2018, which might indicate an increasing  
21 interest in the subject. Interestingly, no publications were found in 2009  
22 and 2010, which is not to say that no research was conducted in that  
23 period. Overall, quantitative research was more prevalent than  
24 qualitative research.  
25  
26  
27  
28  
29  
30

31 Figure 3 presents the classification of the literature based on the types  
32 of services and cancers found in the literature. The number of papers  
33 dealing with 'Diagnostics' stands out ( $n = 27$ ), followed by studies  
34 concerned with 'Treatment' and 'Screening' ( $n = 7$  and  $n = 6$ ,  
35 respectively). The category 'Other' included studies related to efficiency  
36 and emergency admissions ( $n = 4$ ). Studies on diagnostics mainly  
37 involved multiple types of cancer. We identified five emerging and  
38 important themes related to cancer care services, namely hospital  
39 emergency admissions, fast track diagnostics, efficient delivery of  
40 cancer care services, delay in diagnosis and waiting time to treatment,  
41 and barriers to care. Figure 4 shows the distribution of these themes  
42 according to the cancer specialties. Delay in diagnosis and waiting time  
43 to treatment is the most common theme in the surveyed studies ( $n = 15$ ),  
44 followed by efficient delivery of care services ( $n = 10$ ). The next most  
45 frequent theme is fast track diagnostics ( $n = 8$ ), followed by access  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8 barriers to care (n = 7). Studies on fast track diagnostics mainly covered  
9 multiple cancer types (n = 5). Finally, the majority of lung cancer studies  
10 explored issues related to delay in diagnosis and waiting time to  
11 treatment (n = 5).  
12  
13

14  
15 The derived causal loop diagrams feature emerging themes. Further  
16 analyses describe the relations between factors in the form of causal  
17 trees. Each subsequent subsection conveys a causes tree related to a  
18 specific theme and further discusses the theme. The theme *delayed*  
19 *diagnosis and waiting time to treatment* is further split into *delay in*  
20 *diagnosis*, and *treatment delay*. Given the complexity of the problem,  
21 each individual causes tree may fail to capture the intricate connections  
22 among variables, as there may be common factors that influence  
23 multiple themes. However, the discussion will be general enough to  
24 cover other parts of the diagram related to the theme.  
25  
26  
27  
28  
29  
30  
31  
32

33 To complement the analysis concerning individual themes, Appendix  
34 A features a comprehensive picture of the system as a whole in the form  
35 of a causal loop diagram. It conveys the relationship among distinct  
36 influences of different themes, as well as the connections between the  
37 themes in terms of common influences. Even though we cannot claim  
38 that the resulting diagram is a complete picture of reality, it depicts the  
39 perceptions of the surveyed studies regarding the complex issues  
40 connected to the delivery of cancer care.  
41  
42  
43  
44  
45  
46  
47

### 48 3.1. Access barriers to care 49

50  
51 Figure 5 presents a causes tree highlighting factors that can  
52 compromise the access to cancer care services. Administrative barriers  
53 include poor communication and service configuration, as well as the  
54 lack of a uniform service standard for all patients (Cusimano *et al.*,  
55 2019). Anxiety may result from a poor relationship between doctor and  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8 patient (Clarke *et al.*, 2014), from the natural apprehension regarding a  
9 possible cancer diagnosis (Huddy *et al.*, 2016), or the increased tension  
10 due to a delayed diagnosis (Nessim *et al.*, 2015).  
11

12  
13 Obesity and other co-morbidities may affect the access of patients to  
14 the point of care and produce delays in the diagnosis (Guldbrandt *et al.*,  
15 2015). Obesity in particular has been associated with stigma and poor  
16 communication on the part of the service provider (Cusimano *et al.*,  
17 2019). The cultural reluctance in seeking help contributes to delay in  
18 diagnosis and treatment, which may lead to patients presenting with late-  
19 stage cancer (Huddy *et al.*, 2016).  
20

21  
22 Concerning financial aspects, patients from deprived areas have been  
23 found more prone to late-stage diagnosis (Maclean *et al.*, 2015) and  
24 more likely to require emergency care (Maringe *et al.*, 2018). Somewhat  
25 correlated are geographical factors, such as the distance to the available  
26 cancer centres (Turner *et al.*, 2017), the area of residence of patients  
27 (Maclean *et al.*, 2015), which is also correlated to deprivation indices  
28 (Tin Tin *et al.*, 2018; Tsang *et al.*, 2013) and the availability of  
29 diagnostic procedures and treatments in the vicinity (Huddy *et al.*, 2016).  
30 Unsurprisingly, longer travel times to cancer centres and residing in a  
31 deprived area are associated with poorer patient outcomes.  
32

33  
34 The knowledge of patients regarding the cancer types, the treatments,  
35 and the awareness concerning the benefits of early treatment, play an  
36 important role in the outcomes (Redaniel *et al.*, 2015; Momberg *et al.*,  
37 2017). Better informed patients tend to make better decisions regarding  
38 screening and diagnostic strategies, thereby improving early  
39 presentation indices. Finally, the understanding and trust underlying the  
40 patient-doctor relationship are also important to accelerate diagnosis and  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8 thereby improve outcomes, particularly in paediatric cancers (Clarke *et*  
9 *al.*, 2014).

### 12 3.2. Efficient delivery of care pathways

14  
15 Figure 6 summarises strategies proposed and implemented to deliver  
16 improved and faster pathways. Generally, developing a cancer pathway  
17 involves prescribing performance measures and planning in accordance  
18 with these measures for post implementation and monitoring. Efficient  
19 delivery, in turn, demands leadership, coordination, information  
20 technology systems, and governance (Pitter *et al.*, 2019).

25  
26 Multidisciplinary teams have a leading role in cancer care delivery.  
27 Because of this importance, multidisciplinary team meetings should be  
28 held frequently to avoid delays in diagnosis (Redaniel *et al.*, 2015; Van  
29 Huizen *et al.*, 2018). The literature suggests that a well-defined hierarchy  
30 can contribute to speed up treatment decisions and develop automated  
31 decisions for simple cases (Lamb *et al.*, 2014; Redaniel *et al.*, 2015). For  
32 rare cancer types, information technology can help identify courses of  
33 treatment when specialists are scarce (Kasper *et al.*, 2018).

36  
37 Rapid one-stop pathways have also been demonstrated effective for  
38 certain types of cancer (Bass *et al.*, 2018; Haddow *et al.*, 2016), and cost-  
39 effective in a more generalist setting (Sewell *et al.*, 2020). Also essential  
40 for the delivery of a care pathway is the existence of early intervention  
41 or screening programs (Cariou *et al.*, 2018) and the proper definition and  
42 application of standardised pathways (Hoverman *et al.*, 2011; Kubal *et*  
43 *al.*, 2016; Quan *et al.*, 2012). This is to ensure that personalised  
44 diagnostic plans are coherent and independent of the team overseeing  
45 the pathway, and that the best experiences are shared with management  
46 and fellow specialists.

1  
2  
3  
4  
5  
6  
7  
8 Finally, effective delivery of care requires administrative support that  
9 ensures seamless access to associated services such as psychological  
10 assistance (Franchi *et al.*, 2013) and rehabilitation services (Stout *et al.*,  
11 2019). The administrative support may be a part of the cancer service  
12 which acts as a bridge between the cancer service and the associated  
13 service that is required. These supportive services may not have direct  
14 impact on the delivery of cancer pathways, nonetheless they provide  
15 support which may improve patients' experience.  
16  
17  
18  
19  
20  
21

### 22 3.3. Hospital emergency admission

23  
24 Figure 7 depicts the main factors that contribute to hospital  
25 emergency admissions, according to the reviewed literature. These  
26 include age, deprivation, and comorbidity with other physical illnesses  
27 (Kreys *et al.*, 2014; Maringe *et al.*, 2018; Tsang *et al.*, 2013).  
28  
29  
30

31 Emergency visits can follow a GP referral (Black *et al.*, 2015;  
32 Guldbrandt *et al.*, 2015) or be completely unplanned (Ortiz-Ortiz *et al.*,  
33 2016). In the context of cancer pathways, unplanned emergency visits  
34 are in general a symptom of a failure in the proper delivery of care that  
35 results, for example, in late-stage diagnosis. Hence, proper prevention  
36 and screening policies (Cariou *et al.*, 2018) as well as improved cancer  
37 awareness in primary care can help mitigate hospital emergency  
38 admissions in cancer care (Kreys *et al.*, 2014; Tsang *et al.*, 2013),  
39 provided that proper care is available for the patient (Turner *et al.*, 2017).  
40  
41  
42  
43  
44  
45  
46  
47

### 48 3.4. Fast track diagnostics

49  
50 Figure 8 summarises the factors associated with the implementation  
51 of fast track cancer pathways. Reported benefits of fast track programs  
52 include shorter diagnostic intervals and faster access to first treatment,  
53 as well as standardised protocols for a referral to secondary care  
54 (Guldbrandt *et al.*, 2015; Jensen *et al.*, 2014; Prades *et al.*, 2011; Sewell  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8 *et al.*, 2020). However, the results reported in the literature are often  
9 myopic, for they fail to consider the additional burdens imposed on non  
10 fast track patients. Unfortunately, the latter group is comprised of the  
11 majority of patients (Zhou *et al.*, 2018).  
12  
13

14  
15 Fast track services often resort to dedicated resources and prioritised  
16 use of installed capacity which intuitively lead to better delivery of care  
17 for prioritised patients (Jakobsen and Jensen, 2016; Van Harten *et al.*,  
18 2018). However, it is important to contrast such an improvement with  
19 the eventual degradation of the delivery of care for non-prioritised  
20 patients.  
21  
22  
23  
24

### 25 26 27 3.5. *Delay in diagnosis and waiting time to treatment*

28  
29 Figure 9 highlights the contributing factors to the delay in diagnosis.  
30 As expected, there are some overlaps with the factors that lead to  
31 efficient delivery, which would be expected to prevent unnecessary  
32 delays. Figure 10 highlights the main issues that contribute to the pre-  
33 treatment and post-diagnostic delays, according to the surveyed  
34 literature.  
35  
36  
37  
38

39  
40 Early diagnosis and treatment are of the utmost importance in cancer  
41 care, hence it is no surprise that time to first treatment and time to  
42 diagnosis are among the performance functions evaluated in cancer care  
43 (Black *et al.*, 2015; Nessim *et al.*, 2015). Delayed diagnosis can be due  
44 to administrative and systemic issues, primary care delivery, or patient  
45 related issues (Hansen *et al.*, 2011). Patient delays are correlated to  
46 socio-demographic characteristics, such as gender, awareness of cancer,  
47 economic status, alcohol intake, and tobacco consumption (Hansen *et*  
48 *al.*, 2008; Huddy *et al.* 2016; Lim *et al.*, 2014).  
49  
50  
51  
52  
53  
54  
55

56 System delay may stem from unnecessary or delayed diagnostic  
57 procedures (Chiarelli *et al.*, 2017; Laerum *et al.*, 2020; Héquet *et al.*  
58  
59

2017) but also from a tendency of admitting late-stage patients in the system (Forrest *et al.*, 2014; Nessim *et al.*, 2015; Redaniel *et al.*, 2013). Unsurprisingly, better communication between primary and secondary care, and better qualified personnel can help mitigate system delay (Black *et al.*, 2015). Administrative issues include mismanagement of patient transfers between services and levels of care (Iachina *et al.*, 2017), as well as inadequate management of referral, consultation, and booking for treatment (Stokstad *et al.*, 2019; Wasserman *et al.*, 2015).

A central nurse-led coordination of cancer care has been associated with improved outcomes and better delivery of cancer services (Aarhus *et al.*, 2019; Blakely *et al.*, 2015; Wulff *et al.*, 2012). One possible reason for this is the proximity and empathy between nurses and patients (Tod *et al.*, 2015).

#### 4. Discussion

The study has identified literature pertaining to factors as well as strategies associated with the delivery of cancer care pathways from presentation to diagnosis and treatment. The analysis using qualitative mapping, in this case a causal loop diagram, revealed that factors and strategies are interlinked. It highlighted the complexity of the cancer care pathways in general, and that factors influencing a certain part of the cancer care pathway may also affect other areas in the pathway.

Access barriers to care are acknowledged in many passages of the surveyed literature, and the issues that lead to such barriers are important to both primary and secondary care. Studies that investigated access barriers sometimes have done so from the perspective of individual patients and other times have contemplated the perspective of the service providers. Factors associated with access barriers, from the patient

1  
2  
3  
4  
5  
6  
7  
8 perspective, include socio-economic status, demographic profile, or  
9 comorbidity with other physical health conditions. These support  
10 previous reviews, such as Macleod *et al.* (2009) and Williams *et al.*  
11 (2019). The literature showed that these factors are not only associated  
12 with access to primary care but also with hospital emergency access  
13 (Tsang *et al.*, 2013) or even hospital admissions in general.  
14  
15  
16  
17

18 Lack of knowledge about a certain cancer program available in the  
19 community or regarding cancer itself is a recurring theme in the  
20 literature. Such knowledge is invaluable not only for the population at  
21 risk but also for health professionals (Williams *et al.*, 2019). It is not  
22 difficult to see that a lack of understanding about the benefits of  
23 screening programs for certain types of cancer, or about the associated  
24 diagnostic procedures, can affect the decision of individual patients on  
25 whether or not to join screening initiatives (Momborg *et al.*, 2017). In a  
26 certain ethnicity, the lack of knowledge and awareness of cancer can be  
27 found in both developed countries (Jones *et al.*, 2014) or developing  
28 countries (Akuoko *et al.*, 2017).  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 Studies have identified a system of healthcare factors associated with  
39 the delivery of the cancer care pathway. In general, these might relate to  
40 resources such as availability of certain diagnostic procedures or  
41 treatments, the availability of experts in rare cancers, the management  
42 of diagnosis and treatment pathways, the communication between health  
43 professionals and the patients, and between service providers. These  
44 factors highlight gaps in accessing quality care in some European  
45 countries (Kasper *et al.*, 2018). Multidisciplinary support via  
46 multidisciplinary team meetings play an important role in cancer care  
47 delivery (Lamb *et al.*, 2014; Van Huizen *et al.*, 2018). The effectiveness  
48 of the multidisciplinary teams depends upon the implemented strategies.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8 These include prioritising cases based on the type and condition of the  
9 tumour and making decisions for simple cases based on a standardised  
10 cancer pathway (Lamb *et al.*, 2014).  
11

12  
13 Patient related factors together with the healthcare system contributed  
14 to delays in diagnosis and receiving first cancer treatment (Hansen *et al.*,  
15 2011; Huddy *et al.*, 2016). Raising cancer awareness in the community,  
16 and better coordination and communication between service providers  
17 are amongst suggested strategies to mitigate the delays (Black *et al.*,  
18 2015).  
19

20  
21 The study did not limit the delivery of care pathways for specific  
22 cancers or services. The results showed that at a high-level abstraction,  
23 factors influencing delivery at a certain phase of cancer care might be  
24 similar regardless of the cancer types. The analyses give insights into the  
25 complex care pathways, capturing not only primary care but also  
26 secondary and even tertiary care. As a result, the study presented a  
27 preliminary model toward a comprehensive description of factors and  
28 strategies influencing cancer care processes. Such a model, which  
29 provides a comprehensive knowledge regarding the cancer care  
30 pathways, may support the decision making process (Butler *et al.*, 2013).  
31  
32

33  
34 Finally, an apparent gap in the literature is the lack of studies  
35 analysing the holistic effects of cancer pathways in the health system  
36 (Zhou *et al.*, 2018). In particular, the literature lacks studies evaluating  
37 the decrease in the quality of service for patients competing for the same  
38 resources when cancer care is prioritised.  
39

#### 40 41 42 43 44 45 46 47 48 49 50 51 *4.1 Strategies and recommendations*

52  
53 Although some findings in the literature are limited to a given setting,  
54 this section exploits recurring conclusions that can be used to inform  
55 policy making in general and help optimise cancer care pathways.  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8 Firstly, it has been found that cancer awareness is positively correlated  
9 with improved outcomes and early presentation. Hence, we recommend  
10 developing policies to raise cancer awareness in the community, as well  
11 as continuous training and information exchange with healthcare  
12 professionals in primary care. Early intervention and screening plans are  
13 also very important to ensure early presentation. The intervention should  
14 be tailored to the context and address an individual's issues related to  
15 access barriers (Detterbeck *et al.*, 2013).  
16  
17  
18  
19  
20  
21

22 Multidisciplinary teams and discussion boards should also be  
23 included in the pathways to improve outcomes and recommendations.  
24 However, these discussions should be frequent enough to prevent these  
25 meetings from becoming a bottleneck that delays diagnosis. The  
26 multidisciplinary teams should establish automated decisions for  
27 simpler cases to speed up diagnosis. This may be supported by extending  
28 the role of the cancer nurse specialists in the multidisciplinary teams.  
29  
30  
31  
32  
33  
34

35 Pathways should be standardised to ensure that diagnostic plans are  
36 independent of the team overseeing the pathway, and information  
37 exchange should guarantee that the best experiences are shared with  
38 management and fellow specialists. The pathways should provide a  
39 comprehensive cancer care program, be implemented, and subject to  
40 regular update (Christensen *et al.*, 2017). In addition, proper information  
41 technology (IT) support and rapid access to associated services such as  
42 psychological assistance and rehabilitation services should be ensured  
43 to improve outcomes.  
44  
45  
46  
47  
48  
49  
50

51 Finally, fast track diagnostics should be considered to speed up  
52 treatment decisions. However, the planning of a fast track service should  
53 consider the impact to all patients that make use of the shared resource  
54 that would be prioritised, to make sure that the overall effect is positive.  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8 To avoid delays, preemptive measures should also be considered to  
9 prevent delays related to socio-economic and demographic  
10 characteristics. Finally, a channel should be established between primary  
11 and secondary care, as such a channel has been associated with delay  
12 mitigation (Brown *et al.*, 2014).  
13  
14  
15  
16  
17

#### 18 *4.2 Study limitation*

19

20  
21 Due to the keywords and inclusion criteria used for the literature  
22 search, the study may not have covered the literature in its entirety. The  
23 search was limited to articles published in journals. Future studies may  
24 update this effort and include grey literature such as policy and  
25 organisational reports.  
26  
27  
28

29  
30 The resultant causal loop diagram model was developed using  
31 combined factors and strategies discussed in the included studies. In  
32 addition, the quality of each study was not assessed and has not been  
33 taken into account in the analysis. Hence, the resulting diagram might  
34 capture the subjectivity of the authors in summarizing the results, as well  
35 as biases found in the studies. Further research might contest and refine  
36 the model by including more evidence from studies. Others might take  
37 some ideas presented in the model and turn them into a quantitative  
38 model that can be used to investigate the interrelationship between the  
39 factors. Such a quantitative model might capture not only the patient  
40 flow in the cancer care system but also the factors influencing the flow.  
41  
42  
43  
44  
45  
46  
47  
48

49  
50 The study is limited to cancer care pathways in relation to diagnostic  
51 and treatment delivery. Factors related to patient outcomes such as  
52 survival and quality of life were not included. Future studies may include  
53 literature discussing patient outcomes in relation to cancer care  
54 pathways. The inclusion of such literature may highlight the important  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8 links between other support care pathways and the diagnostic and  
9 treatment care pathways. This would be a step towards capturing a  
10 holistic view of healthcare systems in cancer care.  
11  
12

## 13 14 15 **5. Conclusion**

16  
17 Factors influencing the delivery of cancer pathways are myriad and  
18 complex. In general, the factors may relate to the individual patient or  
19 the system of care. Factors such as patient characteristics, socio-  
20 economic conditions, knowledge of cancer and cancer symptoms are  
21 interrelated and influence different cancer services. The results not only  
22 highlighted the factors associated with delay in diagnosis or treatment,  
23 but also the strategies proposed in the literature to deliver timely cancer  
24 pathways, such as fast track diagnostics.  
25  
26  
27  
28  
29  
30

31 The successful delivery of cancer pathways was supported by factors  
32 such as IT and information systems, multidisciplinary teams, and case  
33 management, among others. However, the number of studies found is  
34 not large, especially with respect to specific cancer types. More studies  
35 are needed on the successful delivery of cancer pathways, particularly  
36 focusing on specific cancer types, as different cancers require distinct  
37 cancer pathways.  
38  
39  
40  
41  
42  
43

44 This study provided, by means of a causal loop diagram, a  
45 comprehensive picture of the factors influencing cancer care. The  
46 resulting model developed in the study can be regarded as a preliminary  
47 model representing complex cancer care pathways. Future studies  
48 should confirm or mitigate the links between factors by including up-to-  
49 date evidence. The findings give rise to recommendations and insights  
50 that can guide practitioners in the development of new and the  
51 refinement of existing cancer care pathways.  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Conflict of interest

None.

### References

Aarhus, R., Tjørnhøj-Thomsen, T., Tarp, B., Vedsted, P. and Andersen, R.S. (2019), "Coordinating objects of care: Exploring the role of case managers as brokers in cancer patient pathways", *European Journal of Cancer Care*, Vol. 28 No. 3, p.e13017, doi:10.1111/ecc.13017.

Akuoko, C., Armah, E., Sarpong, T., Quansah, D., Amankwaa, I. and Boateng, D. (2017), "Barriers to early presentation and diagnosis of breast cancer among African women living in Sub-Saharan Africa", *PLoS ONE* Vol. 12 No. 2, p.e0171024, doi:10.1371/journal.pone.0171024.

Allen, D., Purkis, M. E., Rafferty, A. M. and Obstfelder, A. (2019), "Integrating preparation for care trajectory management into nurse education: Competencies and pedagogical strategies", *Nursing Inquiry*, Vol. 26 No. 3, p.e12289, doi: 10.1111/nin.12289.

Altini, M., Solinas, L., Bucchi, L., Gentili, N., Gallegati, D., Balzi, W., Falcini, F. and Massa, I. (2020). "Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways", *International Journal of Environmental Research and Public Health*, Vol. 17 No. 13, p.4765, doi: 10.3390/ijerph17134765.

Alzahouri, K., Velten, M., Arveux, P., Woronoff-Lemsi, M.C., Jolly, D. and Guillemin, F. (2008), "Management of SPN in France. Pathways for definitive diagnosis of solitary pulmonary nodule: A multicentre

1  
2  
3  
4  
5  
6  
7  
8 study in 18 French districts”, *BMC Cancer* Vol. 8 No. 1, p.93,  
9 doi:10.1186/1471-2407-8-93.  
10

11 Bass, E., Freeman, A., Jameson, C., Punwani, S., Moore, C., Arya, M.,  
12 Emberton, M. and Ahmed, H. (2018), “Prostate cancer diagnostic  
13 pathway: Is a one-stop cognitive MRI targeted biopsy service a  
14 realistic goal in everyday practice? A pilot cohort in a tertiary referral  
15 centre in the UK”, *BMJ Open* Vol. 8 No. 10, p.e024941, doi:10.1136/  
16 bmjopen-2018-024941.  
17  
18  
19  
20  
21

22  
23 Black, G., Sheringham, J., Spencer-Hughes, V., Ridge, M., Lyons, M.,  
24 Williams, C., Fulop, N. and Pritchard-Jones, K. (2015), “Patients’  
25 experiences of cancer diagnosis as a result of an emergency  
26 presentation: A qualitative study”, *PLoS ONE* Vol. 10 No. 8,  
27 p.e0135027, doi:10.1371/journal.pone.0135027.  
28  
29  
30  
31

32  
33 Blakely, T., Collinson, L., Kvizhinadze, G., Nair, N., Foster, R., Dennett,  
34 E. and Sarfati, D. (2015), “Cancer care coordinators in stage III colon  
35 cancer: A cost-utility analysis”, *BMC Health Services Research* Vol.  
36 15 No. 306, doi:10.1186/s12913-015-0970-5.  
37  
38  
39

40  
41 Bosscher, M., Van Leeuwen, B. and Hoekstra, H. (2015), “Current  
42 management of surgical oncologic emergencies”, *PLoS ONE* Vol. 10  
43 No. 5, p.e0124641, doi:10.1371/journal.pone.0124641.  
44  
45

46  
47 Brown, S., Castelli, M., Hunter, D. J., Erskine, J., Vedsted, P., Foot, C.  
48 and Rubin, G. (2014), “How might healthcare systems influence speed  
49 of cancer diagnosis: a narrative review”, *Social Science &*  
50 *Medicine*, Vol. 116 No. 100, pp.56-63, doi:  
51 10.1016/j.socscimed.2014.06.030.  
52  
53  
54  
55

56  
57 Butler, J., Foot, C., Bomb, M., Hiom, S., Coleman, M., Bryant, H.,  
58 Vedsted, P., Hanson, J., Richards, M. and ICBP Working Group.  
59

(2013), “The international cancer benchmarking partnership: an international collaboration to inform cancer policy in Australia, Canada, Denmark, Norway, Sweden and the United Kingdom”, *Health Policy*, Vol. 112 No. 1-2, pp.148-155, doi: 10.1016/j.healthpol.2013.03.021.

Cancer Care Ontario (2019), “Lung Cancer Diagnosis Pathway Map”. [online] Ontario Health. Available from <https://www.cancercareontario.ca/en/pathway-maps/lung-cancer>. [Accessed 07 May 2019].

Cariou, A., Rouzier, R., Baffert, S., Soilly, A.L. and Héquet, D. (2018), “Multidimensional impact of breast cancer screening: Results of the multicenter prospective optisoins01 study”, *PLoS ONE* Vol. 13 No. 8, p.e0202385, doi:10.1371/journal.pone.0202385.

Chiarelli, A., Muradali, D., Blackmore, K., Smith, C., Mirea, L., Majpruz, V., O’Malley, F., Quan, M. and Holloway, C. (2017), “Evaluating wait times from screening to breast cancer diagnosis among women undergoing organised assessment vs usual care”, *British Journal of Cancer* Vol. 116 No. 10, pp.1254–1263, doi:10.1038/bjc.2017.87.

Christensen, N. L., Jekunen, A., Heinonen, S., Dalton, S. O. and Rasmussen, T. R. (2017). “Lung cancer guidelines in Sweden, Denmark, Norway and Finland: a comparison”, *Acta Oncologica*, Vol. 56 No. 7, pp.943-948, doi: 10.1080/0284186X.2017.1315172.

Clarke, R., Jones, C., Mitchell, C. and Thompson, M. (2014), “Shouting from the roof top: A qualitative study of how children with leukaemia are diagnosed in primary care”, *BMJ Open* Vol. 4 No. 2, p.e004640, doi:10.1136/bmjopen-2013-004640.

1  
2  
3  
4  
5  
6  
7  
8 Currie, V. L. and Harvey, G. (2000), "The use of care pathways as tools  
9 to support the implementation of evidence-based practice", *Journal of*  
10 *Interprofessional Care*, Vol. 14 No. 4, pp.311-324, doi:  
11 10.1080/13561820020003874.  
12  
13  
14

15 Cusimano, M.C., Simpson, A.N., Han, A., Hayeems, R., Bernardini,  
16 M.Q., Robertson, D., Kives, S.L., Satkunaratham, A., Baxter, N.N. and  
17 Ferguson, S.E. (2019), "Barriers to care for women with low-grade  
18 endometrial cancer and morbid obesity: A qualitative study", *BMJ*  
19 *Open* Vol. 9 No. 6, p.e026872, doi:10.1136/bmjopen-2018-026872.  
20  
21  
22  
23  
24

25 Department of Health, (2007), "Cancer Reform Strategy", London:  
26 Department of Health. [online] Available from  
27 [https://webarchive.nationalarchives.gov.uk/20130104165259/http://w](https://webarchive.nationalarchives.gov.uk/20130104165259/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_081006)  
28 [ww.dh.gov.uk/en/Publicationsandstatistics/Publications/Publications](http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_081006)  
29 [PolicyAndGuidance/DH\\_081006](http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_081006). [Accessed 30 September 2020].  
30  
31  
32  
33  
34

35 Department of Health and Human Services (2016), "Optimal Care  
36 Pathway for People with Lung Cancer". [online] Cancer Australia and  
37 Cancer Council. Available from  
38 [https://www.cancer.org.au/content/ocp/health/optimal-care-pathway-](https://www.cancer.org.au/content/ocp/health/optimal-care-pathway-for-people-with-lung-cancer-june-2016.pdf)  
39 [for-people-with-lung-cancer-june-2016.pdf](https://www.cancer.org.au/content/ocp/health/optimal-care-pathway-for-people-with-lung-cancer-june-2016.pdf). [Accessed 07 May 2019].  
40  
41  
42  
43

44 Delilovic, S., Hasson, H., Åhström, M. and von Knorring, M. (2019),  
45 "Implementing standardized cancer patient pathways (CPPs) – a  
46 qualitative study exploring the perspectives of health care  
47 professionals", *BMC Health Service Research* Vol. 19 No. 577, doi:  
48 10.1186/s12913-019-4413-6.  
49  
50  
51  
52  
53

54 Detterbeck, F. C., Mazzone, P. J., Naidich, D. P. and Bach, P. B. (2013).  
55 "Screening for lung cancer: diagnosis and management of lung cancer:  
56 American College of Chest Physicians evidence-based clinical  
57  
58  
59  
60

practice guidelines”, *Chest*, Vol. 143 No. 5, p.e78S-e92S, doi: 10.1378/chest.12-2350.

Donetto, S., Desai, A., Zoccatelli, G., Robert, G., Allen, D., Brearly, S. and Raffetty, A. M. (2019), "Organisational strategies and practices to improve care using patient experience data in acute NHS hospital trusts: an ethnographic study", *Health Services and Delivery Research*, NIHR Journals Library, Southampton (UK), Vol. 34 No. 7, doi: 10.3310/hsdr07340.

Franchi, G., Bulli, F., Muraca, M., Maruelli, A., Grechi, E. and Miccinesi, G. (2013), "Impact of a psycho-oncological rehabilitation intervention on psychological distress: The experience of CeRiON (Oncological Rehabilitation Centre) Florence 2007-2010", *Supportive Care in Cancer* Vol. 21 No. 9, pp.2381–2386, doi:10.1007/s00520-013-1803-x.

Forrest, L. F., Adams, J., White, M. and Rubin, G. (2014), "Factors associated with timeliness of post-primary care referral, diagnosis and treatment for lung cancer: population-based, data-linkage study", *British Journal of Cancer*, Vol. 111 No. 9, pp.1843-1851. doi: 10.1038/bjc.2014.472.

Gesme, B. and Wiseman, M. (2011), "Strategic use of clinical pathways", *Journal of Oncology Practice* Vol. 7 No. 1, pp.54–56, doi:10.1200/JOP.2010.000193.

Guldbrandt, L., Fenger-Grøn, M., Rasmussen, T., Jensen, H. and Vedsted, P. (2015), "The role of general practice in routes to diagnosis of lung cancer in Denmark: A population-based study of general practice involvement, diagnostic activity and diagnostic intervals",



1  
2  
3  
4  
5  
6  
7  
8 *BMC Health Services Research* Vol. 15 No. 21, doi:10.1186/s12913-  
9 014-0656-4.

10  
11 Haddow, J.B., Walshe, M., Aggarwal, D., Thapar, A., Hardman, J.,  
12 Wilson, J., Oshowo, A., Bhan, C. and Mukhtar, H. (2016), “Improving  
13 the diagnostic stage of the suspected colorectal cancer pathway: A  
14 quality improvement project”, *Healthcare* Vol. 4 No. 3, pp.225–234,  
15 doi: 10.1016/j.hjdsi.2015.09.004.

16  
17  
18  
19  
20  
21 Hansen, R., Olesen, F., Sørensen, H., Sokolowski, I., Søndergaard, J.  
22 (2008), “Socioeconomic patient characteristics predict delay in cancer  
23 diagnosis: A Danish cohort study”, *BMC Health Services Research*  
24 Vol. 8 No. 49, doi:10.1186/1472-6963-8-49.

25  
26  
27  
28  
29 Hansen, R., Vedsted, P., Sokolowski, I., Søndergaard, J. and Olesen, F.  
30 (2011), “Time intervals from first symptom to treatment of cancer: A  
31 cohort study of 2,212 newly diagnosed cancer patients”, *BMC Health*  
32 *Services Research* Vol. 11 No. 284, doi:10.1186/1472-6963-11-284.

33  
34  
35  
36  
37 Hoverman, J.R., Cartwright, T.H., Patt, D.A., Espirito, J.L., Clayton,  
38 M.P., Garey, J.S., Kopp, T.J., Kolodziej, M., Neubauer, M., Fitch, K.,  
39 Pyenson, B. and Beveridge, R. (2011), “Pathways, outcomes, and costs  
40 in colon cancer: Retrospective evaluations in two distinct databases”,  
41 *Journal of Oncology Practice* Vol. 7 No. 3S, pp.52s–59s,  
42 doi:10.1200/JOP.2011.000318.

43  
44  
45  
46  
47  
48 Huddy, J., Weldon, S.M., Ralhan, S., Painter, T., Hanna, G., Kneebone,  
49 R. and Bello, F. (2016), “Sequential simulation (sqs) of clinical  
50 pathways: A tool for public and patient engagement in point-of-care  
51 diagnostics”, *BMJ Open* Vol. 6, p.e011043. doi:10.1136/bmjopen-  
52 2016-011043.

1  
2  
3  
4  
5  
6  
7  
8 Héquet, D., Huchon, C., Baffert, S., Alran, S., Reyal, F., Nguyen, T.,  
9 Combes, A., Trichot, C., Alves, K., Berseneff, H. and Rouzier, R.  
10 (2017), “Preoperative clinical pathway of breast cancer patients:  
11 Determinants of compliance with EUSOMA quality indicators”,  
12 *British Journal of Cancer* Vol. 116 No.11, pp.1394–1401, doi:10.  
13 1038/bjc.2017.114.  
14  
15  
16  
17

18  
19 Iachina, M., Jakobsen, E., Fallesen, A. and Green, A. (2017), “Transfer  
20 between hospitals as a predictor of delay in diagnosis and treatment of  
21 patients with non-small cell lung cancer - a register based cohort-  
22 study”, *BMC Health Services Research* Vol. 17 No. 267,  
23 doi:10.1186/s12913-017-2230-3.  
24  
25  
26  
27

28  
29 Jakobsen, J. K. and Jensen, J. B. (2016). “DaPeCa-2: Implementation of  
30 fast-track clinical pathways for penile cancer shortens waiting time  
31 and accelerates the diagnostic process—a comparative before-and-after  
32 study in a tertiary referral centre in Denmark”, *Scandinavian Journal*  
33 *of Urology*, Vol. 50 No. 1, pp.80-87, doi:  
34 10.3109/21681805.2015.1077472.  
35  
36  
37  
38

39  
40 Jensen, H., Tørring, M.L., Olesen, F., Overgaard, J. and Vedsted, P.  
41 (2014), “Cancer suspicion in general practice, urgent referral and time  
42 to diagnosis: a population-based GP survey and registry study”, *BMC*  
43 *Cancer*, Vol. 14 No. 636, doi:10.1186/1471-2407-14-636.  
44  
45  
46  
47

48 Jensen, H., Tørring, M.L. and Vedsted, P. (2017), “Prognostic  
49 consequences of implementing cancer patient pathways in Denmark:  
50 A comparative cohort study of symptomatic cancer patients in primary  
51 care”, *BMC Cancer* Vol. 17 No. 627, doi:10.1186/s12885-017-3623-  
52 8.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8 Jones, C., Maben, J., Jack, R., Davies, E., Forbes, L., Lucas, G. and  
9 Ream, E. (2014), “A systematic review of barriers to early presentation  
10 and diagnosis with breast cancer among Black women”, *BMJ Open*  
11 Vol. 4 No. 2, p.e004076, doi:10.1136/ bmjopen-2013-004076.  
12  
13

14  
15 Kasper, B., Lecointe-Artzner, E., Wait, S., Boldon, S., Wilson, R.,  
16 Gronchi, A., Valverde, C., Eriksson, M., Dumont, S., Drove, N., Kanli,  
17 A. and Wartenberg, M. (2018), “Working to improve the management  
18 of sarcoma patients across Europe: A policy checklist”, *BMC Cancer*  
19 Vol. 18 No. 424, doi:10.1186/s12885-018-4320-y.  
20  
21  
22  
23

24  
25 Kreys, E., Kim, T., Delgado, A. and Koeller, J. (2014), “Impact of cancer  
26 supportive care pathways compliance on emergency department visits  
27 and hospitalizations”, *Journal of Oncology Practice* Vol. 10 No. 3,  
28 pp.168–173, doi:10.1200/JOP.2014.001376.  
29  
30  
31

32  
33 Kubal, T., Letson, D., Chiappori, A., Springett, G., Shimkhada, R.,  
34 Tamondong Lachica, D. and Peabody, J. (2016), “Longitudinal cohort  
35 study to determine effectiveness of a novel simulated case and  
36 feedback system to improve clinical pathway adherence in breast, lung  
37 and GI cancers”, *BMJ Open* Vol. 6 No. 9, p.e012312,  
38 doi:10.1136/bmjopen-2016-012312.  
39  
40  
41  
42  
43

44  
45 Laerum, D., Brustugun, O. T., Gallefoss, F., Falk, R., Strand, T. E. and  
46 Fjellbirkeland, L. (2020), “Reduced delays in diagnostic pathways for  
47 non-small cell lung cancer after local and National initiatives”, *Cancer*  
48 *Treatment and Research Communications*, Vol. 23, p.e100168, doi:  
49 10.1016/j.ctarc.2020.100168.  
50  
51  
52  
53

54  
55 Lamb, B. W., Jalil, R. T., Sevdalis, N., Vincent, C. and Green, J. S. A.  
56 (2014), “Strategies to improve the efficiency and utility of  
57 multidisciplinary team meetings in urology cancer care: A survey  
58  
59  
60

study”, *BMC Health Services Research* Vol. 14 No. 377, doi:10.1186/1472-6963-14-377.

Lawson, D., Revelino, K. and Owen, D. (2006), "Clinical pathways to improve patient outcomes", *Physical Therapy Reviews*, Vol. 11 No. 4, pp.269-272, doi: 10.1179/108331906X144118.

Lim, A. W., Ramirez, A. J., Hamilton, W., Sasieni, P., Patnick, J. and Forbes, L. J. (2014), “Delays in diagnosis of young females with symptomatic cervical cancer in England: an interview-based study”, *British Journal of General Practice*, Vol. 64 No. 627, p.e602-e610, doi: 10.3399/bjgp14X681757.

Littlejohns, L. B., Baum, F., Lawless, A. and Freman, T (2018), “The value of a causal loop diagram in exploring the complex interplay of factors that influence health promotion in a multisectoral health system in Australia”, *Health Research Policy and System* Vol. 16 No. 126, doi: 10.1186/s12961-018-0394-x.

Lung Clinical Expert Group (2017), “National Optimal Lung Cancer Pathway”, [online] Available from [https://www.cancerresearchuk.org/sites/default/files/national\\_optimal\\_lung\\_pathway\\_aug\\_2017.pdf](https://www.cancerresearchuk.org/sites/default/files/national_optimal_lung_pathway_aug_2017.pdf). [Accessed 05 April 2019].

Maclean, R., Jeffreys, M., Ives, A., Jones, T., Verne, J. and Ben-Shlomo, Y. (2015), “Primary care characteristics and stage of cancer at diagnosis using data from the National Cancer Registration Service, quality outcomes framework and general practice information”, *BMC Cancer* Vol. 15 No. 500, doi:10.1186/s12885-015-1497-1.

1  
2  
3  
4  
5  
6  
7  
8 Macleod, U., Mitchell, E., Burgess, C., Macdonald, S. and Ramirez, A.  
9 (2009), “Risk factors for delayed presentation and referral of  
10 symptomatic cancer: Evidence for common cancers”, *British Journal*  
11 *of Cancer* Vol. 101, pp.S92– S101, doi:10.1038/sj.bjc.6605398.

12  
13  
14  
15  
16 Maringe, C., Rachet, B., Lyratzopoulos, G. and Rubio, F. (2018),  
17 “Persistent inequalities in unplanned hospitalisation among colon  
18 cancer patients across critical phases of their care pathway, England,  
19 2011-13”, *British Journal of Cancer* Vol. 119 No. 5, pp.551–557,  
20  
21 doi:10.1038/s41416-018-0170-2.

22  
23  
24  
25 Momberg, M., Botha, M., Van Der Merwe, F. and Moodley, J. (2017),  
26 “Women’s experiences with cervical cancer screening in a colposcopy  
27 referral clinic in Cape Town, South Africa: A qualitative analysis”,  
28  
29 *BMJ Open* Vol. 7, p.e013914, doi: 10.1136/bmjopen-2016-013914.

30  
31  
32  
33 Nessim, C., Winocour, J., Holloway, D., Saskin, R. and Holloway, C.  
34 (2015), “Wait times for breast cancer surgery: Effect of magnetic  
35 resonance imaging and preoperative investigations on the diagnostic  
36 pathway”, *Journal of Oncology Practice* Vol. 11 No. 2, pp.e131–e138,  
37  
38 doi:10.1200/JOP.2014.002105.

39  
40  
41  
42  
43 Ortiz-Ortiz, K., Ros-Motta, R., Marn-Centeno, H., Cruz-Correa, M. and  
44 Ortiz, A. (2016), “Factors associated with late stage at diagnosis  
45 among Puerto Rico’s government health plan colorectal cancer  
46 patients: A cross-sectional study”, *BMC Health Services Research*  
47  
48 Vol. 16 No. 344, doi:10.1186/s12913-016-1590-4.

49  
50  
51  
52 Pitter, J., Csanádi, M., Szigeti, A., Lukács, G., Kovács, Á., Moizs, M.,  
53  
54 Repa, I., Zemplényi, A., Czypionka, T., Kraus, M., Rutten-Van  
55  
56 Mólken, M. and Kaló, Z. (2019), “Planning, implementation and  
57  
58 operation of a personalized patient management system for subjects  
59  
60

with first suspect of cancer (Onkonetwork): System description based on a qualitative study”, *BMC Health Services Research* Vol. 19 No. 131, doi:10.1186/s12913-019-3957-9.

Prades, J., Espinàs, J., Font, R., Argimon, J. and Borràs, J. (2011), “Implementing a Cancer Fast-track Programme between primary and specialised care in Catalonia (Spain): A mixed methods study”, *British Journal of Cancer* Vol. 105 No. 6, pp.753–759, doi:10.1038/bjc.2011.308.

Prager, G.W., Braga, S., Bystricky, B., Qvortrup, C., Criscitiello, C., Esin, E., Sonke, G.S., Martínez, G.A., Frenel, J., Karamouzis, M., Strijbos, M., Yazici, O., Bossi, P., Banerjee, S., Troiani, T., Eniu, A., Ciardiello, F., Taberner, J.Z., Zielinski, C.C., Casali, P.G., Cardoso, F., Douillard, J., Jezdic, S., McGregor, K., Bricalli, G., Vyas, M. and Ilbawi, A. (2018), “Global cancer control: responding to the growing burden, rising costs and inequalities in access”, *ESMO Open* Vol. 3 No. 2, p.e000285, doi:10.1136/esmoopen-2017-000285.

Quan, M., Shumak, R., Majpruz, V., Holloway, C., O’Malley, F. and Chiarelli, A. (2012), “Improving work-up of the abnormal mammogram through organized assessment: Results from the Ontario Breast Screening Program”, *Journal of Oncology Practice* Vol. 8 No. 2, pp.107–112, doi:10.1200/JOP.2011.000413.

Queen Mary University of London (2017), “New research reveals one in two people in the UK will get cancer”. [online] Available from <https://www.qmul.ac.uk/wolfson/about-us/news/items/new-research-reveals-one-in-two-people-in-the-uk-will-get-cancer.html> [Accessed 12 January 2021].

1  
2  
3  
4  
5  
6  
7  
8 Redaniel, M., Martin, R., Gillatt, D., Wade, J. and Jeffrey, M. (2013),  
9 “Time from diagnosis to surgery and prostate cancer survival: A  
10 retrospective cohort study”, *BMC Cancer* Vol. 13 No. 559,  
11 doi:10.1186/1471-2407-13-559.  
12  
13

14  
15 Redaniel, M., Ridd, M., Martin, R., Coxon, F., Jeffrey, M. and Wade,  
16 J. (2015), “Rapid diagnostic pathways for suspected colorectal cancer:  
17 Views of primary and secondary care clinicians on challenges and their  
18 potential solutions”, *BMJ Open* Vol. 5 No. 10, p.e008577,  
19 doi:10.1136/bmjopen-2015-008577.  
20  
21  
22  
23

24  
25 Saghatchian, M., Thonon, F., Boomsma, F., Hummel, H., Koot, B.,  
26 Harrison, C., Rajan, A., De Valeriola, D., Otter, R., Pontes, J.,  
27 Lombardo, C., McGrath, E., Ringborg, U., Tursz, T. and Van Harten,  
28 W. (2014), “Pioneering quality assessment in European cancer centers:  
29 A data analysis of the organization for European cancer institutes  
30 accreditation and designation program”, *Journal of Oncology Practice*  
31 Vol. 10 No. 5, pp.e342–e349, doi:10.1200/JOP.2013.001331.  
32  
33  
34  
35  
36  
37

38 Schrijvers, G., van Hoorn, A., and Huiskes, N. (2012), "The care  
39 pathway: concepts and theories: an introduction", *International*  
40 *Journal of Integrated Care*, Vol. 12 (Spec Ed Integrated Care  
41 Pathways), p.e192, doi: 10.5334/ijic.812.  
42  
43  
44  
45

46 Sewell, B., Jones, M., Gray, H., Wilkes, H., Lloyd-Bennett, C., Beddow,  
47 K., Bevan, M. and Fitzsimmons, D. (2020), “Rapid cancer diagnosis  
48 for patients with vague symptoms: a cost-effectiveness study”, *British*  
49 *Journal of General Practice* Vol. 70 No. 692, pp.e186–e192,  
50 doi:10.3399/bjgp20X708077.  
51  
52  
53  
54

55 Stermann, J. (2000), *Business Dynamics: Systems Thinking and Modeling*  
56 *for a Complex World*, Irwin/McGraw-Hill.  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8 Stokstad, T., Sørhaug, S., Amundsen, T., and Grønberg, B. H. (2019),  
9 “Reasons for prolonged time for diagnostic workup for stage I-II lung  
10 cancer and estimated effect of applying an optimized pathway for  
11 diagnostic procedures”, *BMC Health Services Research*, Vol. 19 No.  
12 679, pp.1-9, doi: 10.1186/s12913-019-4517-z.

13  
14  
15  
16  
17 Stout, N., Sleight, A., Pfeiffer, D., Galantino, M. and deSouza, B.  
18 (2019), “Promoting assessment and management of function through  
19 navigation: opportunities to bridge oncology and rehabilitation  
20 systems of care”, *Supportive Care in Cancer* Vol. 27 No. 12, pp.4497-  
21 4505, doi:10.1007/ s00520-019-04741-0.

22  
23  
24  
25  
26  
27 Tin Tin, S., Elwood, J., Brown, C., Sarfati, D., Campbell, I., Scott, N.,  
28 Ramsaroop, R., Seneviratne, S., Harvey, V. and Lawrenson, R. (2018),  
29 “Ethnic disparities in breast cancer survival in New Zealand: Which  
30 factors contribute?”, *BMC Cancer* Vol. 18 No. 1, p.58, doi:10.1186/  
31 s12885-017-3797-0.

32  
33  
34  
35  
36  
37 Tod, A., Redman, J., McDonnel, A., Borthwick, D. and White, J. (2015),  
38 “Lung cancer treatment rates and the role of the lung cancer nurse  
39 specialist: A qualitative study”, *BMJ Open* Vol. 5 No.12, p.e008587,  
40 doi:10.1136/ bmjopen-2015-008587.

41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51 Tsang, C., Bottle, A., Majeed, A. and Aylin, P. (2013), “Cancer  
52 diagnosed by emergency admission in England: An observational  
53 study using the general practice research database”, *BMC Health  
54 Services Research* Vol. 13 No. 308, doi:10.1186/1472-6963-13-308.

55  
56  
57  
58  
59  
60  
Turner, M., Fielding, S., Ong, Y., Dibben, C., Feng, Z., Brewster, D.,  
Black, C., Lee, A. and Murchie, P. (2017), “A cancer geography  
paradox? Poorer cancer outcomes with longer travelling times to  
healthcare facilities despite prompter diagnosis and treatment: A data-



linkage study”, *British Journal of Cancer* Vol. 117 No. 3, pp.439–449, doi:10.1038/bjc.2017.180.

Van Harten, W., Goedbloed, N., Boekhout, A. and Heintzbergen, S. (2018), “Implementing large scale fast track diagnostics in a comprehensive cancer center, pre- and post-measurement data”, *BMC Health Services Research* Vol. 18 No. 85, doi:10.1186/s12913-018-2868-5.

Van Huizen, L., Dijkstra, P., Van Der Laan, B., Reintsema, H., Ahaus, K., Bijl, H. and Roodenburg, J. (2018), “Multidisciplinary first-day consultation accelerates diagnostic procedures and throughput times of patients in a head-and-neck cancer care pathway, a mixed method study”, *BMC Health Services Research* Vol. 18 No. 820, doi:10.1186/s12913-018-3637-1.

Wang, F. and Onega, T. (2015), “Accessibility of cancer care: disparities, outcomes and mitigation”, *Annals of GIS* Vol. 21 No. 2, pp.119–125, doi:10.1080/19475683.2015. 1007893.

Wasserman, D., Boulos, M., Hopman, W., Booth, C., Goodwin, R. and Biagi, J. (2015), “Reasons for delay in time to initiation of adjuvant chemotherapy for colon cancer”, *Journal of Oncology Practice* Vol. 11 No. 1, pp.e28– e35, doi:10.1200/JOP.2014.001531.

Weller, D., Vedsted, P., Rubin, G., Walter, F., Emery, J., Scott, S., Campbell, C., Andersen, R.S., Hamilton, W., Olesen, F., Rose, P., Nafees, S., van Rijswijk, E., Hiom, S., Muth, C., Beyer, M., and Neal, R.D. (2012), “The Aarhus statement: improving design and reporting of studies on early cancer diagnosis”, *British Journal of Cancer* Vol. 106 No. 7, pp.1262–1267, doi:10.1038/bjc.2012.68.


1  
2  
3  
4  
5  
6  
7  
8 Williams, P., Murchie, P. and Bond, C. (2019), “Patient and primary care  
9 delays in the diagnostic pathway of gynaecological cancers: a  
10 systematic review of influencing factors”, *British Journal of General  
11 Practice* Vol. 69 No. 679, pp.e106–e111, doi:  
12 10.3399/bjgp19X700781.  
13  
14  
15


16  
17 World Health Organization (2018), “Cancer”, [online] Available  
18 from: [https://www.who.int/  
19 news-room/fact-sheets/detail/cancer](https://www.who.int/news-room/fact-sheets/detail/cancer).  
20 [Accessed 01 May 2019].  
21  
22

23 Wulff, C., Vedsted, P. and Søndergaard, J. (2012), “A randomised  
24 controlled trial of hospital-based case management to improve  
25 colorectal cancer patients’ health-related quality of life and evaluations  
26 of care”, *BMJ Open* Vol. 2 No. 6, p.e001481, doi:10.1136/bmjopen-  
27 2012-001481.  
28  
29  
30  
31

32  
33 Wulff, C.N., Thygesen, M., Søndergaard, J. and Vedsted, P. (2008),  
34 “Case management used to optimize cancer care pathways: a  
35 systematic review”, *BMC Health Services Research* Vol. 8 No. 227,  
36 doi: 10.1186/1472-6963-8-227.  
37  
38  
39


40  
41 Zhou, Y., Mendonca, S., Abel, G., Hamilton, W., Walter, F., Johnson,  
42 S., Shelton, J., Elliss-Brookes, L., McPhail, S. and Lyratzopoulos, G.  
43 (2018), “Variation in ‘fast-track’ referrals for suspected cancer by  
44 patient characteristic and cancer diagnosis: Evidence from 670 000  
45 patients with cancers of 35 different sites”, *British Journal of Cancer*  
46 Vol. 118 No. 1, pp.24–31, doi:10.1038/bjc.2017.381.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60













1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41









1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41






1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41



Appendix A



Source	Title	Method
Hansen <i>et al.</i> , 2008	Socioeconomic patient characteristics predict delay in cancer diagnosis: A Danish cohort study.	Quantitative
Hansen <i>et al.</i> , 2011	Time intervals from first symptom to treatment of cancer: A cohort study of 2,212 newly diagnosed cancer patients	Quantitative
Prades <i>et al.</i> , 2011	Implementing a cancer fast-track programme between primary and specialised care in Catalonia (Spain): A mixed methods study.	Quantitative & Qualitative
Hoverman <i>et al.</i> , 2011	Pathways, outcomes, and costs in colon cancer: retrospective evaluations in two distinct databases.	Quantitative
Wulf <i>et al.</i> , 2012	A randomised controlled trial of hospital-based case management to improve colorectal cancer patients' health-related quality of life and evaluations of care	Quantitative

1 2 3 4 5 6 7 8 9 10 11	Quan <i>et al.</i> , 2012	Improving work-up of the abnormal mammogram through organized assessment: Results from the Ontario Breast Screening Program	Quantitative
12 13 14 15 16 17	Redaniel <i>et al.</i> , 2013	Time from diagnosis to surgery and prostate cancer survival: A retrospective cohort study	Quantitative
18 19 20 21 22 23 24 25 26 27 28	Tsang <i>et al.</i> , 2013	Cancer diagnosed by emergency admission in England: An observational study using the general practice research database	Quantitative
29 30 31 32 33 34 35	Lamb <i>et al.</i> , 2014	Strategies to improve the efficiency and utility of multidisciplinary team meetings in urology cancer care: A survey study	Quantitative
36 37 38 39 40 41 42 43 44	Jensen <i>et al.</i> , 2014	Cancer suspicion in general practice, urgent referral and time to diagnosis: A population-based GP survey and registry study	Quantitative
45 46 47 48 49 50 51 52 53	Clarke <i>et al.</i> , 2014	'Shouting from the roof tops': A qualitative study of how children with leukaemia are diagnosed in primary care	Qualitative
54 55 56 57 58 59 60	Kreys <i>et al.</i> , 2014	Impact of cancer supportive care pathways compliance on emergency department visits and hospitalizations	Quantitative

1 2 3 4 5 6 7 8 9	Lim <i>et al.</i> , 2014	Delays in diagnosis of young females with symptomatic cervical cancer in England: An interview-based study	Quantitative
10 11 12 13 14 15	Forrest <i>et al.</i> , 2014	Factors associated with timeliness of post-primary care referral, diagnosis and treatment for lung cancer: Population-based, data-linkage study	Quantitative
16 17 18 19 20 21 22 23 24	Black <i>et al.</i> , 2015	Patients' experiences of cancer diagnosis as a result of an emergency presentation: A qualitative study	Qualitative
25 26 27 28 29 30	Wasserman <i>et al.</i> , 2015	Reasons for delay in time to initiation of adjuvant chemotherapy for colon cancer	Quantitative
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46	Maclean <i>et al.</i> , 2015	Primary care characteristics and stage of cancer at diagnosis using data from the national cancer registration service, quality outcomes framework and general practice information	Quantitative
47 48 49 50 51 52 53 54 55 56 57 58 59 60	Guldbrandt <i>et al.</i> , 2015	The role of general practice in routes to diagnosis of lung cancer in Denmark: A population-based study of general practice involvement, diagnostic activity and diagnostic intervals 21	Quantitative



1 2 3 4 5 6 7 8 9	Tod <i>et al.</i> , 2015	Lung cancer treatment rates and the role of the lung cancer nurse specialist: A qualitative study	Qualitative
10 11 12 13 14 15 16 17	Redaniel <i>et al.</i> , 2015	Rapid diagnostic pathways for suspected colorectal cancer: Views of primary and secondary care clinicians on challenges and their potential solutions	Qualitative
18 19 20 21 22 23 24 25 26 27 28 29	Nessim <i>et al.</i> , 2015	Wait times for breast cancer surgery: Effect of magnetic resonance imaging and preoperative investigations on the diagnostic pathway	Quantitative
30 31 32 33 34 35	Blakely <i>et al.</i> , 2015	Cancer care coordinators in stage III colon cancer: A cost-utility analysis	Quantitative
36 37 38 39 40 41 42	Kubal <i>et al.</i> , 2016	Longitudinal cohort study to determine effectiveness of a novel simulated case and feedback system to improve clinical pathway adherence in breast, lung and GI cancers	Quantitative
43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	Ortiz-Ortiz <i>et al.</i> , 2016	Factors associated with late stage at diagnosis among Puerto Rico's government health plan colorectal cancer patients: A cross-sectional study	Quantitative

Haddow <i>et al.</i> , 2016	Improving the diagnostic stage of the suspected colorectal cancer pathway: A quality improvement project	Quantitative & Qualitative
Jakobsen and Jensen, 2016	DaPeCa-2: Implementation of fast-track clinical pathways for penile cancer shortens waiting time and accelerates the diagnostic process - A comparative before-and-after study in a tertiary referral centre in Denmark	Quantitative
Huddy <i>et al.</i> , 2016	Sequential simulation (SqS) of clinical pathways: A tool for public and patient engagement in point-of-care diagnostics	Qualitative
Turner <i>et al.</i> , 2017	A cancer geography paradox? Poorer cancer outcomes with longer travelling times to healthcare facilities despite prompter diagnosis and treatment: A data-linkage study	Quantitative
Héquet <i>et al.</i> , 2017	Preoperative clinical pathway of breast cancer patients: Determinants of compliance with EUSOMA quality indicators	Quantitative
Chiarelli <i>et al.</i> , 2017	Evaluating wait times from screening to breast cancer diagnosis among women undergoing organised assessment vs usual care	Quantitative

1 2 3 4 5 6 7 8 9	lachina <i>et al.</i> , 2017	Transfer between hospitals as a predictor of delay in diagnosis and treatment of patients with Non-Small Cell Lung Cancer - A register based cohort-study	Quantitative
10 11 12 13 14 15 16 17 18 19	Momberg <i>et al.</i> , 2017	Women's experiences with cervical cancer screening in a colposcopy referral clinic in Cape Town, South Africa: A qualitative analysis	Qualitative
20 21 22 23 24 25 26 27 28	Van Huizen <i>et al.</i> , 2018	Multidisciplinary first-day consultation accelerates diagnostic procedures and throughput times of patients in a head-and-neck cancer care pathway, a mixed method study	Quantitative & Qualitative
29 30 31 32 33 34 35 36 37	Bass <i>et al.</i> , 2018	Prostate cancer diagnostic pathway: Is a one-stop cognitive MRI targeted biopsy service a realistic goal in everyday practice? A pilot cohort in a tertiary referral centre in the UK	Quantitative
38 39 40 41 42 43 44 45 46 47 48 49	Maringe <i>et al.</i> , 2018	Persistent inequalities in unplanned hospitalisation among colon cancer patients across critical phases of their care pathway, England, 2011–13	Quantitative
50 51 52 53 54 55 56 57 58 59 60	Cariou <i>et al.</i> , 2018	Multidimensional impact of breast cancer screening: Results of the multicenter prospective optisoins01 study	Quantitative

1 2 3 4 5 6 7 8 9 10	Kasper <i>et al.</i> , 2018	Working to improve the management of sarcoma patients across Europe: A policy checklist	Qualitative
11 12 13 14 15 16 17 18 19 20 21	Van Harten <i>et al.</i> , 2018	Implementing large scale fast track diagnostics in a comprehensive cancer center, pre- and post-measurement data	Quantitative
22 23 24 25 26 27 28 29 30 31	Tin Tin <i>et al.</i> , 2018	Ethnic disparities in breast cancer survival in New Zealand: Which factors contribute?	Quantitative
32 33 34 35 36 37	Zhou <i>et al.</i> , 2018	Variation in 'fast-track' referrals for suspected cancer by patient characteristic and cancer diagnosis: Evidence from 670 000 patients with cancers of 35 different sites	Quantitative
38 39 40 41 42 43 44 45 46 47 48	Cusimano <i>et al.</i> , 2019	Barriers to care for women with low-grade endometrial cancer and morbid obesity: A qualitative study	Qualitative
49 50 51 52 53 54 55 56 57 58 59 60	Aarhus <i>et al.</i> , 2019	Coordinating objects of care: Exploring the role of case managers as brokers in cancer patient pathways	Qualitative

Pitter <i>et al.</i> , 2019	Planning, implementation and operation of a personalized patient management system for subjects with first suspect of cancer (OnkoNetwork): System description based on a qualitative study	Qualitative
Stokstad <i>et al.</i> , 2019	Reasons for prolonged time for diagnostic workup for stage I-II lung cancer and estimated effect of applying an optimized pathway for diagnostic procedures	Quantitative
Sewell <i>et al.</i> , 2020	Rapid cancer diagnosis for patients with vague symptoms: a cost-effectiveness study	Quantitative
Laerum <i>et al.</i> , 2020	Reduced delays in diagnostic pathways for non-small cell lung cancer after local and National initiatives	Quantitative

DD Delay in diagnosis  
WTTT Waiting time to treatment  
HEA Hospital emergency admission

Cancer	Service	Theme
Multi cancers	Diagnostic	DD and WTTT
Multi cancers	Diagnostic	DD and WTTT
Multi cancers	Diagnostic	Fast Track Diagnostics
Colorectal	Treatment	Efficient Delivery
Colorectal	Treatment	DD and WTTT

Breast	Diagnostic	Efficient Delivery
Prostate	Treatment	DD and WTTT
Multi cancers	Screening	HEA
Urology	Other	Efficient Delivery
Multi cancers	Diagnostic	Fast Track Diagnostics
Leukaemia	Diagnostic	Barriers to Care
Multi cancers	Treatment	HEA

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Cervical	Diagnostic	DD and WTTT
Lung	Treatment	DD and WTTT
Multi cancers	Screening	HEA
Colon	Diagnostic	DD and WTTT
Multi cancers	Diagnostic	Barriers to Care
Lung	Screening	Fast Track Diagnostics



Lung	Treatment	DD and WTTT
Colorectal	Screening	Fast Track Diagnostics
Breast	Diagnostic	DD and WTTT
Colon	Treatment	DD and WTTT
Multi cancers	Other	Efficient Delivery
Colorectal	Diagnostic	HEA

Colorectal	Diagnostic	Efficient Delivery
Penile	Diagnostic	Fast Track Diagnostics
Oesophagogastric	Diagnostic	Barriers to Care
Multi cancers	Diagnostic	Barriers to Care
Breast	Diagnostic	DD and WTTT
Breast	Screening	DD and WTTT

Lung	Diagnostic	DD and WTTT
Cervical	Screening	Barriers to Care
Head and Neck	Diagnostic	Efficient Delivery
Prostate	Diagnostic	Efficient Delivery
Colon	Other	HEA
Breast	Screening	Efficient Delivery

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Sarcoma	Other	Efficient Delivery
Multi cancers	Diagnostic	Fast Track Diagnostics
Breast	Diagnostic	Barriers to Care
Multi cancers	Diagnostic	Fast Track Diagnostics
Endometrial	Diagnostic	Barriers to Care
Multi cancers	Diagnostic	Efficient Delivery

Multi cancers	Diagnostic	Efficient Delivery
Lung	Diagnostic	DD and WTTT
Multi cancers	Diagnostic	Fast Track Diagnostics
Lung	Diagnostic	DD and WTTT

Geographical source	Sample size and data source
Aarhus, Denmark	GP questionnaire on patient's diagnostic pathway (2212), Patients questionnaires on socioeconomic characteristics (1252).
Aarhus, Denmark	Population-based cohort of 2,212 patients. Data from administrative registries and questionnaires completed by GP.
Spain	Hospitals' patient records (56020), semistructured interview (83) with health professionals and administrators.
US	Clinical records from an Electronic Health Record database to evaluate survival (910). Claims data from a national administrative claims database to examine direct medical costs (220).
Denmark	A total of 280 colorectal cancer patients, 140 for each group (with CM and usual care).

1 2 3 4 5 6 7 8 9 10 11	Ontario, Canada	Clinical records of 25,543 women provided by the Integrated Clinical Management System database. The proportion underwent the work-up through BAA is 39% and through UC is 61%.
12 13 14 15 16 17	England, the UK	Cancer registries from the South West Public Observatory, Hospital Episode Statistics and Office of National Statistics for mortality. Total participants 17,043 men.
18 19 20 21 22 23 24 25 26 27 28	England, the UK	General Practice Research Database (GPRD), 74763 patients. Integrated Hospital Episode Statistics (HES), . Office for National Statistics (ONS) mortality data.
29 30 31 32 33 34 35	UK	Health professional involved in MDT across the UK (173 participants).
36 37 38 39 40 41 42 43 44	Denmark	Population size is 3,823. Data is from GP and national register.
45 46 47 48 49 50 51 52 53	England, the UK	Participants: 21 patients and 9 GPs.
54 55 56 57 58 59 60	USA	4,144 records on therapy from 3,191 patients. Database from the CareFirst claims.

1 2 3 4 5 6 7 8 9	England, the UK	128 female patients aged under 30 years, with a recent diagnosis of cervical cancer in England. Data sources: primary care records and National Cervical Screening Database.
10 11 12 13 14 15	England, the UK	28,733 patient level data obtained from the Northern and Yorkshire Cancer Registry and Information Centre (NYCRIS, 2012)
16 17 18 19 20 21 22 23 24	England, the UK	27 participants.
25 26 27 28 29 30	Canada	Medical records of 580 patients with colon cancer.
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46	England, the UK	Cancer registry from the National cancer Registration Service, Quality Outcome Framework, GP survey and GP workforce census. Breast cancer: 40,251; Prostate cancer: 34,231; Colorectal cancer: 31,414; lung cancer: 33,027.
47 48 49 50 51 52 53 54 55 56 57 58 59 60	Denmark	971 lung cancer incidences from Danish Cancer Registry (DCR) and GP questionnaires.



1 2 3 4 5 6 7 8 9	England, the UK	Purposive sampling. A total of 24 participants took part in interviews; a total of 60 clinical staff attended MDT meetings; a total of 6 LCNSs attended group interviews.
10 11 12 13 14 15 16 17	The UK	Purposive sampling of 24 clinicians.
18 19 20 21 22 23 24 25 26 27 28 29	Canada	Retrospective data of 264 women with breast cancer.
30 31 32 33 34 35	New Zealand	New Zealand data on colon cancer incidence, survival, and mortality.
36 37 38 39 40 41 42	Florida, USA	48 providers at Moffitt Cancer Center (MCC)
43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	Puerto Rico	A total of 190 colorectal cancer patients from Puerto Rico Central Cancer Registry (PRCCR) and the PRHIA databases.

The UK	30 patients for interview and 29 individuals for workshop.
Denmark	263 patient records from medical records and administrative systems.
England, the UK	38 participants.
Scotland, the UK	12,339 patients. Database was provided by the Health Authority (NHS Grampian) Cancer Care Pathway (CCPd).
France	604 patients. Data from operable breast cancer patients recorded in participating hospitals.
Ontario, Canada	9044 patient records from Ontario Breast Screening Program (OBSP).

Denmark	11,273 patient records provided by the Danish Lung Cancer Registry (DLCR).
Cape Town, South Africa	27 women who were first time colposcopy clinic attendees at a tertiary hospital colposcopy clinic.
Netherlands	89 patient records retrieved from medical records.
The UK	112 male patients identified through referral at prostate cancer one stop clinic.
England, the UK	65,020 records patients with colon cancer, linked with the Hoapital Episode Statistics (HES) in-patients and A&E datasets.
France	379 patients aged between 50 and 74 years identified from screening records.

Europe	NA
Netherlands	175 patient records from cancer centre.
New Zealand	13,657 patient records provided by Auckland and Waikato Breast Cancer Registers. The registers were linked to National Cancer Registry, Mortality Collection, and the National Minimum Dataset.
England, the UK	66,9220 patients provided by the national Cancer Data Repository (NCDR).
Toronto, Canada	15 patients with endometrial cancer.
Denmark	13 patients and 26 healthcare professionals

Hungary	20 interviews with representatives of key stakeholder including: 1 programme manager, 2 programme initiators, 1 financial expert, 4 physicians, 8 non-physician health care professionals, 2 patients, and 2 informal caregivers.
Norway	100 patient records from hospital database.
The UK	1000 patients were simulated using real data from Neath Port Talbot Hospital (NPTH) Rapid Diagnostic Centre.
Norway	780 patient records from hospital database.

1	
2	<b>Purpose</b>
3	
4	To examines whether patients' socioeconomic
5	characteristics are predictors of long patient-, doctor-
6	and system-related delay in cancer diagnosis.
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	To explore patient-, general practitioner (GP)- and
24	system-related delay in the interval from first cancer
25	symptom to diagnosis and treatment, and to analyse
26	the extent to which delays differ by cancer type.
27	
28	
29	
30	
31	To analyse the implementation and overall
32	effectiveness of cancer fast-track programme.
33	
34	
35	
36	
37	
38	
39	To evaluate the clinical outcomes and the economic
40	impact of adherence to level I Pathways, an evidence-
41	based oncology treatment program in the treatment
42	of colon cancer.
43	
44	
45	
46	To analyse the effectiveness of hospital-based case
47	management (CM) in terms of patient-reported
48	outcomes.
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

1  
2 To evaluate outcomes of women undergoing work-  
3 up after abnormal mammogram through a formal  
4 breast assessment affiliate (BAA) program with  
5 explicit care pathways compared with usual care  
6 (UC) using developed quality indicators for screening  
7 mammography programs.  
8  
9

10  
11  
12 To investigate the association between waiting time,  
13 from diagnosis to surgery, and the patient's survival.  
14  
15

16  
17  
18 To determine the incidence of first-ever diagnoses of  
19 cancer by emergency (unplanned) admission and  
20 identify patient-level risk factors for these diagnoses  
21 in England.  
22  
23

24  
25  
26 To evaluate the implementation of MDT, and  
27 identify interventions and strategies to improve the  
28 efficiency and productivity of the MDT meeting.  
29  
30

31  
32  
33 To analyse the association between the cancer  
34 suspicion by GP and the time to diagnosis, and  
35 between the choice of using cancer patient  
36 pathways and the time to diagnosis.  
37  
38

39  
40  
41 To investigate the prehospital presentation of  
42 paediatric leukaemia and identify the disease and  
43 non-disease related factors which facilitate or  
44 impede diagnosis.  
45  
46

47  
48  
49 To evaluate the effects of pathway compliance to  
50 supportive care agents on ED visits and  
51 hospitalizations attributed to chemotherapy-induced  
52 adverse effect.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 To examine the extent and determinants of delays in  
3 diagnosis of young females with symptomatic  
4 cervical cancer.  
5  
6  
7  
8  
9

10 To investigate the factors influencing timely post-  
11 primary care referral, diagnosis and treatment for  
12 lung cancer.  
13  
14  
15

16 To understand how the emergency presentation  
17 arise of patients who received cancer diagnosis  
18 following the ED visit.  
19  
20  
21  
22  
23

24 To examine factors associated with delay in time to  
25 adjuvant chemotherapy.  
26  
27  
28  
29  
30

31 To investigate association of primary care  
32 characteristics and stage of cancer at diagnostic  
33 phase.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 To describe the routes to cancer diagnosis, the  
48 diagnosis activity preceding diagnosis and the  
49 diagnosis intervals for lung cancer.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2 To examine the role of Lung Cancer Nurse Specialist  
3 (LCNS) in care pathways.  
4  
5  
6  
7  
8

9  
10 To ascertain the challenges associated with  
11 implementation of the 2-week wait referral criteria  
12 and waiting time targets for colorectal cancer and to  
13 identify recommendations for improvements to the  
14 pathway.  
15  
16  
17

18 To determine the overall wait time and identify  
19 factors associated to overall wait time from  
20 identification of an imaging abnormality to definitive  
21 treatment in women with breast cancer.  
22  
23  
24  
25  
26  
27  
28  
29

30 To evaluate the effectiveness of cancer care  
31 coordination for stage III colon cancer patients.  
32  
33  
34  
35

36 To examine whether a measurement and feedback  
37 system led to improvements in adherence in clinical  
38 pathways.  
39  
40  
41

42 To evaluate factors associated to colorectal cancer  
43 stage at diagnosis including delay in diagnosis.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 To improve the lead-time and the patient experience  
3 of the diagnostic stage of the suspected colorectal  
4 cancer pathway.  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14

15 To examine the feasibility and impact of a fast-track  
16 referral pathway on clinical time intervals from the  
17 first symptom of penile cancer to first treatment.  
18  
19  
20  
21  
22  
23

24 To introduce the sequential simulation as a  
25 methodology to active public and patient  
26 engagement in developing point-of-care tests.  
27  
28  
29  
30  
31  
32  
33  
34

35 To investigate the impact of burden of travel on the  
36 cancer diagnosis process.  
37  
38  
39  
40  
41  
42  
43

44 To describe the preoperative clinical pathway of  
45 breast cancer patients and evaluate the  
46 determinants of compliance with the European  
47 Society of Breast Cancer Specialists (EUSOMA)  
48 quality indicators.  
49  
50

51 To evaluate factors associated with waiting time  
52 from screening to diagnosis for women undergoing  
53 assessment through Breast Assessment Centre (BAC)  
54 and Usual Care (UC).  
55  
56  
57  
58  
59  
60

1 2 3 4 5 6 7 8 9	To find out the influence of transfer between hospitals on waiting time to the diagnosis and treatment for lung cancer.
10 11 12 13 14 15 16 17 18 19	To explore the explore and understand women's experience with cervical cancer screening and referral pathways.
20 21 22 23 24 25 26 27 28	To evaluate the effects of implementing the multidisciplinary first day consultation (MFDC) on efficiency of the care pathway, measured as process indicators throughput times (referral, diagnostic, procedures and start treatment) and number of hospital visits.
29 30 31 32 33 34 35 36 37	To demonstrate the feasibility of a 'one stop', rapid diagnostic prostate cancer pathway, using both multiparametric MRI and transperineal targeted biopsy.
38 39 40 41 42 43 44 45 46 47 48 49	To examine the occurrence of hospital emergency admissions among colon cancer patients on three time periods: 90 days pre-diagnosis, 90 days post diagnosis and 90 days pre-death.
50 51 52 53 54 55 56 57 58 59 60	To evaluate the impact of breast cancer screening on therapeutic management, costs, patients' needs, and working life.

1  
2 To highlight key gaps in research, policy, practice,  
3 and initiatives that may impact the future care of  
4 sarcoma patients in different European countries.  
5  
6  
7  
8  
9

10  
11 To report the process of analysis, redesign,  
12 implementation, organisational dynamics and first  
13 results using a pre and post measurement design.  
14  
15  
16  
17  
18  
19  
20

21  
22 To identify factors associated to cancer survival  
23 within different ethnicities.  
24  
25  
26  
27  
28  
29  
30  
31

32 To examine factors influencing GP's decision to refer  
33 cancer patients through either a fast-track or an  
34 elective GP referral.  
35  
36  
37

38 To understand the experiences of low-grade  
39 endometrial cancer patients with morbid obesity,  
40 from onset to diagnosis to surgery.  
41  
42  
43  
44  
45  
46  
47  
48

49 To explore how care managers (CM) handle their  
50 various responsibilities and focuses on the micro-  
51 politics of case management.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 To provide a quality evaluation of OnkoNetwork  
3 along the components of SELFIE conceptual  
4 framework: service delivery, leadership and  
5 governance, workforce, financing, technologies and  
6 medical products, and information and research.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

20 To identify reasons for delays and estimate the  
21 effect on timeliness when applying on optimal  
22 diagnostic pathway.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 To explore the cost-effectiveness of the Rapid  
34 Diagnostic Centre in its first year of operation  
35 compared with standard clinical practice.  
36  
37  
38  
39

40 To analyse the impact of intervention in cancer  
41 pathways at local and national level to the time to  
42 treatment.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Results**

*Patient delay*: retired female experienced shorter delays than employed female patients. Female smokers experienced longer delays than female non-smokers. *Doctor delay*: female with economic advantage experienced shorter delays than those female with economic disadvantage. Well-educated males experienced shorter delays than men with short education. Male patients experienced longer doctor delays than women. *System delay*: female patients with economic advantage experienced shorter delays than women with economic disadvantage. Female with high alcohol intake experienced longer delays than women with average intake.

Patient delay (median 21 days) and system delay (median 55 days) constituted of most total delay (median 98 days). Different cancer types have different median total delays.

Using the fast-track programme, half of patients with colorectal, lung and breast cancers are diagnosed within 30 days. The fast-track programme contributed to clarifying and accelerating cancer diagnosis and treatment.

Adherence to pathways associated to lower costs of treatment, shorter duration of therapy, and lower rate of hospital admission related to chemotherapy.

There is no evidence to support that CM improve health-related quality of life. However, patients with CM reported more positive care experience compared with those without CM.

1  
2 With respect to timeliness, patients requiring a core or surgical  
3 biopsy were more likely to be diagnosed within 7 weeks through  
4 a BAA compared with those underwent UC.  
5  
6  
7  
8  
9  
10  
11

12 Factors associated with longer waiting time to surgery after  
13 diagnosis include patient's age, geographical location of  
14 patient's residence and the tumor differentiation.  
15  
16  
17

18 Around 13.9% patients diagnosed with cancer for the first time  
19 were diagnosed via emergency admission. Patients of older age  
20 or living in the most deprived area were most at risk of diagnosis  
21 by emergency admission. Patients with multiple number of visits  
22 prior the diagnosis were less likely to be diagnosed by the  
23 emergency route.  
24  
25  
26  
27  
28

29 The efficiency and effectiveness of MDT can be improved by  
30 prioritising cases based on complexity, tumor type, or the  
31 availability of the MDT member.  
32  
33  
34  
35

36 Patients with 'alarm' symptoms were more likely to be referred  
37 to the cancer patient pathways, and shorter waiting time to  
38 diagnosis.  
39  
40  
41  
42  
43  
44

45 The nature of parent-doctor relationship associated with access  
46 to diagnosis pathway. Factors associated with delay in diagnosis  
47 included lack of continuity of GP; some GP's reluctance to take  
48 blood from children; and some parents feeling unable to voice  
49 effectively their concerns.  
50  
51  
52  
53

54 Only G-CSF pathway compliance showed significant association  
55 with decrease in the rate of neutropenia ED  
56 visits/hospitalizations. G-CSF stands for granulocyte colony-  
57 stimulating factors.  
58  
59  
60

1  
2 Patient awareness of cancer symptom contributed to delay in  
3 diagnosis.  
4  
5  
6  
7  
8  
9

10 Factors associated with timely post-primary care referral,  
11 diagnosis and treatment include cancer stage, performance  
12 status, and cancer histology.  
13  
14  
15

16 Delay in receiving diagnosis may caused by repeated cycles of  
17 help-seeking and appraisal. In some cases, system failure due to  
18 clinical decisions that were not consistent with the guideline or a  
19 break down in the pathway to diagnosis.  
20  
21  
22  
23

24 The significant factors associated with delay in receiving  
25 adjuvant chemotherapy were the presence of a postoperative  
26 complication or intercurrent illness and oncologist- or patient-  
27 initiated delay.  
28  
29  
30

31 Patient characteristics such as ethnicity, age, and living in  
32 deprived areas could act as confounders for presenting with  
33 advanced female breast cancer. Whereas age and gender were  
34 important cofounders for presenting with advance lung cancer.  
35 Men living in deprived areas were morelikely to present at  
36 advanced stage for prostate cancer. GP characteristics such as  
37 location, easy access, higher use of TWW and detection rate can  
38 relate to cancer presentation stage for a certain cancer types.  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 The majority of lung cancer patients received diganosis referrals  
49 through GP with some cases undegone the fast-track pathways.  
50 GP's symptom interpretation and the use of fast-track route  
51 were significantly associated with different diagnostic interval.  
52 Patients' education level and age were found significantly  
53 associated with longer primary and diagnostic intervals.  
54  
55  
56  
57  
58  
59  
60



1 2 3 4 5 6 7 8	LCNS plays important role within the multidisciplinary team (MDT) and can act as a catalyst to patient access to treatment. The role involved assessment, managing symptoms, psychological support and information provision.
9 10 11 12 13 14 15 16 17	The study identified challenges in implementing the 2-week referral system. These include patient delay in seeking GP advice and the wait for GP appointment; difficulty in applying the referral guidelines due to vague symptoms and commorbidities.
18 19 20 21 22 23 24 25 26 27 28 29	Factors associated with prolonged wait times included number of operative clinic visits, number of visits to radiology, and initial imaging outside of the centre. Independent factors associated with a decreased wait time include the disease severity, previous history of breast cancer, positive family history, presentation with mass, first imaging abnormality seen on ultrasound.
30 31 32 33 34 35	The nurse cancer care coordinators showed cost-effective if coupled with increase treatment coverage and reduce time to treatment.
36 37 38 39 40 41 42	The study found that measurement and feedback programme significantly improved the adherence to clinical pathways particularly in work up and cancer treatment.
43 44 45 46 47 48 49 50	The logistic regression model estimated that factors associated with late stage cancer to be a diagnostic delay of 60 days or more and having the first contact for a cancer diagnosis through hospital emergency.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 The reduction in lead time from referral to diagnosis was  
3 achieved by implementing new pathway which include features  
4 such as same-day referral triage, implementing straight-to-test as  
5 default triage outcome, reviewing benign disease in a virtual  
6 clinic and discharging patients by letter and telephone, coupling  
7 the secondary imaging with endoscopy slots, and coupling the  
8 MDT with same day clinic appointments.  
9  
10  
11  
12  
13  
14

15 The implementation of Cancer Patient Pathway significantly  
16 reduced the system interval. The reduction was achieved  
17 through prebooking of outpatient clinic appointments and  
18 upfront referrals of all diagnostic procedures. It is also supported  
19 by the cancer coordinator.  
20  
21  
22  
23

24 With respect to diagnostic strategy, the study found key themes.  
25 These are lack of awareness of oesophagogastric cancer, the  
26 existence of barriers to testing and diagnosis, the need for  
27 designing new test device, new clinical pathway, and placement  
28 for test device such as at a GP or a pharmacy.  
29  
30  
31  
32  
33  
34

35 The study found that patients (who develop common cancers)  
36 with increased burden of travel to key healthcare components  
37 (GP practice, cancer diagnosis centre and cancer treatment  
38 centre) received quicker diagnosis and primary treatment.  
39  
40  
41  
42  
43

44 Having multiple examinations within the centre was found  
45 associated with an increased waiting time to surgery. Whereas  
46 having an outpatient breast biopsy was found reducing the  
47 waiting time to surgery.  
48  
49  
50

51 Factors associated with the shorter wait time to diagnosis  
52 include having more procedures per visit, procedures scheduled  
53 in shorter intervals, and imaging or biopsy on their first visit.  
54  
55  
56  
57  
58  
59  
60

1  
2 Patients with transfers between hospitals experienced longer  
3 waiting time in receiving treatment from the point of finishing  
4 the primary investigation. This also means longer waiting time  
5 from referral to receiving treatment.  
6  
7  
8  
9

10 Factors associated with access barrier to cancer care include  
11 negative community opinions relating to having the test and low  
12 encouragement from peers. Factors related to health care  
13 providers include lack of information regarding referral and the  
14 quality of information provided.  
15  
16  
17  
18  
19

20 The implementation of MFDC significantly reduced the  
21 throughput time in the diagnosis and start treatment. However,  
22 implementation of new treatment modalities did not show the  
23 same effect. This was because complex treatment needs more  
24 time and more hospital visits.  
25  
26  
27  
28  
29

30 Implementing the interventions offered in the study (mpMRI  
31 was performed prior to patients attending clinic, on the same  
32 day; results were available within 48 hours and discussed at a  
33 specialist MDT meeting; patients returned for counselling within  
34 7 days) reduced the time to diagnosis and treatment.  
35  
36  
37  
38

39 Patients with colon cancer experienced HEA in all three 90 days  
40 periods, pre-diagnosis, post-diagnosis, and pre-death. In 90 days  
41 pre-diagnosis, over a third of patients experienced at least one  
42 HEA; female patients and those with advanced stage of cancer  
43 experienced more HEAs than their counterparts. Deprivation  
44 and tumor stage (I-III) were found related to proportion of HEA  
45 in all periods.  
46  
47  
48  
49

50 Breast screening found higher proportion patients with earlier  
51 and less aggressive tumor. This lead to a reduced number of  
52 chemotherapies. Direct medical costs accosiated with patients  
53 with screening was less than those without screening.  
54  
55  
56  
57  
58  
59  
60

1  
2 Key areas that support the access to quality cancer care are the  
3 need for development and designated and accredited centres of  
4 reference; more professional training; multidisciplinary care;  
5 greater incentive to research and innovation; and more rapid  
6 access to effective treatments.  
7  
8  
9

10  
11 Implementation of fast-track diagnostics reduced the access and  
12 throughput time to diagnosis. In some cases the implementation  
13 was supported by one-stop-shop design, enabling one day  
14 pathology workup. Other factors involved the close  
15 collaboration between the tumor board and diagnostic  
16 department.  
17  
18  
19  
20

21  
22 Maori and Pacific women had higher risk of excess mortality  
23 from breast cancer. Factors associated with this different risk  
24 include late stage at diagnosis, neighbourhood deprivation,  
25 mode of diagnosis, type of health care facility where primary  
26 cancer treatment was undertaken and type of loco-regional  
27 therapy.  
28  
29  
30  
31

32 Factors influencing variation in proportion of fast-track referral  
33 include cancer site, age, sex, and deprivation.  
34  
35  
36  
37

38 Factors associated with barrier to care include administrative,  
39 geographic and financial challenges. Other factors may related  
40 to patients' and providers' lack of knowledge on endometrial  
41 cancer and its symptoms and poor communication.  
42  
43  
44  
45  
46  
47  
48


49 The case managers' role encompasses caring for the patients  
50 with respect to their illness, their experience in receiving the  
51 care, the organisation, and the cancer patient pathways.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 The study provided comprehensive report in all evaluated areas.  
3 Within the service delivery, elements supported the care  
4 delivery include: 1. patient enrolment to receive priority in care,  
5 personalised care epathway, and timely access to quality care. 2.  
6 Personalised diagnostic plans that comform with the diagnostic  
7 protocols. 3. Coordination and documentation of diagnostic  
8 visits. 4. A multidisciplinary Tumor Board whose responsible in  
9 providing multidisciplinary persolanised diagnostic and  
10 treatment plans. 5. Treatment and follow up which be provided  
11 within the time limit.  
12  
13  
14  
15  
16  
17  
18  
19

20 Factors infleuncing delay in receiving first treatment include  
21 (among others) late referral to a PET CT and for an exercise test  
22 at the first hospital visit, multiple procedures in diagnostic  
23 workup, delay in making decision at tumor board meeting due to  
24 incomplete results. Based on the finding, the optimal pathway  
25 was developed which focuses on reducing times from referral to  
26 star treatment.  
27  
28  
29  
30  
31  
32

33 The simulation model showed that referring patients with vague  
34 symptoms to Rapid Diagnostic Centre can be most cost effective  
35 and reduce time to diagnosis.  
36  
37  
38  
39

40 Factors associated with longer time to treatment include the  
41 severity of the cancer (stage I-III), use of PET-CT for staging,  
42 dianostic procedure at external hospital, and number of  
43 diagnostic precedures.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46